Emergency Information Take Over
Tuesday, August 27, 2013
G. Steven Burrill
Life sciences industry leader will help lead organization to next stage of development
The Global Virus Network (GVN), a coalition of the world’s leading medical virology research centers working to prevent illness and death from viral disease, today announced G. Steven Burrill as the new Chairman of the GVN Board of Directors.
The announcement was made today by Robert C. Gallo, MD, co-founder of the GVN, Chair of GVN’s Scientific Leadership Board, and Director of the Institute of Human Virology at the University of Maryland School of Medicine in Baltimore, Maryland, USA. Dr. Gallo was joined in this announcement by GVN co-founders Reinhard Kurth, MD, of the Ernst Schering Foundation in Berlin, Germany and William Hall, MD, PhD, of the University College Dublin in Ireland.
“I am enthusiastic, really, quite excited to have Steve Burrill as our new GVN Board Chair,” said Dr. Gallo. “He has drive, as well as a deep understanding of how to build operations to improve the health of people globally. These are both critical for GVN as it moves into its next developmental stage,” he added.
As Chair of the Board, G. Steven Burrill brings more than 45 years of biotechnology, financial and entrepreneurial expertise to the GVN.
“GVN’s mission to prevent illness and death from viral diseases globally is a real challenge today, with a much more highly mobile global population, increased urbanization, a growing middle class, and the adaptability of viruses to mutate and find a new home,” said Mr. Burrill, founder and CEO of Burrill & Company, a global financial services firm focused exclusively on the life sciences. “I am happy to lead this organization to bring talent, resources, research, and dedication to solving the global problem. The threats posed by viral disease have never been greater, but neither have the opportunities to address them; technology alone won’t solve the problems we face. We must ensure that the needed policies, funding, and incentives are in place to tackle these global threats.”
Mr. Burrill currently serves on the Boards of Directors of AliveCor (Chairman), Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (NASDAQ: NVDQ), and XDx. Previously, he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Mr. Burrill is a founder and currently serves as Chairman of the Board of the National Science and Technology Medals Foundation (NSTMF). He succeeds Kathleen Kennedy Townsend as GVN’s Chair of the Board of Directors.
About Global Virus Network (GVN)
The Global Virus Network (GVN) is a non-profit, 501(c)(3) organization, comprised of leading medical virologists from more than 20 countries. The GVN’s mission is to combat current and emerging pandemic viral threats through international collaborative research, training the next generation of medical virologists, and advocacy. For more information, please contact Nora Grannell at email@example.com and visit www.gvn.org. Follow us on Twitter @GlobalVlrusNews
University of Maryland School of Medicine
Director of Marketing and Public Relations
(410) 706-1954 (phone)
(410) 706-1952 (fax)